🇺🇸 US

MRNA revenue, net income and debt history (Moderna, Inc.)

Quick answer

Moderna, Inc. (MRNA) reported revenue of $1.94B and net loss of $2.82B for the fiscal year ended 2025-12-31, down 39.9% from $3.24B the year before, per its 10-K filed with the SEC on 2026-02-20. Long-term debt stood at $590.0M.

✓ SEC EDGAR XBRL company facts (10-K/10-Q filings)

Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)

Fiscal yearRevenueNet incomeLong-term debt
2025 (FY ending 2025-12-31)$1.94B-$2.82B$590.0M
2024 (FY ending 2024-12-31)$3.24B-$3.56B$0.0M
2023 (FY ending 2023-12-31)$6.85B-$4.71B—
2022 (FY ending 2022-12-31)$19.26B$8.36B—
2021 (FY ending 2021-12-31)$18.47B$12.20B—
2020 (FY ending 2020-12-31)$803.0M-$747.0M—
2019 (FY ending 2019-12-31)$60.0M-$514.0M—
2018 (FY ending 2018-12-31)$135.1M-$384.7M—
2017 (FY ending 2017-12-31)$205.8M-$255.9M—
2016 (FY ending 2016-12-31)$108.4M-$216.2M—

Related

Last updated 2026-10-16. Data only, not financial or tax advice.